Long-term follow-up study of patients who have previously been exposed to UCART19 (allogeneic engineered T-cells expressing a lentiviral-based anti-CD19 chimeric antigen receptor)
This important study is focused on understanding the long-term health and well-being of patients who have previously been treated with UCART19 for advanced leukaemia. This includes checking for any side effects that might appear over time, how well the treatment continues to control the disease, and whether patients relapse. For younger patients, the study will also look at how the treatment might affect their growth and development through puberty. By carefully following these patients, researchers hope to gain a better understanding of the long-term safety and effectiveness of UCART19, which can help improve future treatments for leukaemia.
At a glance
What is this study about?
This study is an essential follow-up for people who have previously received a cellular therapy called UCART19 for a type of blood cancer called advanced lymphoid leukaemia. Think of it like a long-term check-up to see how everyone is doing after their treatment. The main goal is to carefully monitor how your health is over time, specifically looking for any side effects, often called 'adverse events' in medical terms, that might happen in the months and years after your last UCART19 dose.
Researchers will be keeping a close eye on the number and type of these side effects, how long they last, and what happened as a result of them. They're especially interested in certain serious side effects. For children and teenagers who took part in the earlier UCART19 study, there's an additional focus. Doctors want to understand if the treatment has had any impact on their normal growth, like height and weight, and how they go through puberty.
Beyond understanding side effects, the study will also track how well the UCART19 treatment continues to control the leukaemia. This includes looking at whether the cancer comes back or gets worse (relapse or progression) and how long people live after treatment. The information gathered from this study is vital. It helps doctors learn more about the long-term safety and success of UCART19, which can help improve how this and similar new treatments are used for patients in the future.
Key takeaways
- This study is a long-term follow-up for patients treated with UCART19.
- It aims to understand side effects and patient health over time, especially for advanced leukaemia.
- Children's growth and development will also be monitored.
- No new medication or treatment will be given in this study.
- The information helps improve future care for leukaemia patients.
Who may be eligible?
This study is for adults who have previously received the UCART19 treatment for their advanced lymphoid leukaemia. There isn't an upper age limit, meaning older adults can also be included.
Both men and women are welcome to take part in this follow-up study. The main requirement is simply that you have already been treated with UCART19 in a previous study. If you fit this description, you could be eligible to participate.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- I have been treated with UCART19 in a past study.
- I have been diagnosed with advanced lymphoid leukaemia.
- I am an adult.
- I am willing to have long-term follow-up and health checks.
What does participation involve?
Taking part in this study means you'll be followed up regularly by your medical team after your UCART19 treatment. The main focus is to keep track of your health and any side effects you might experience. This will involve regular check-ups, which may include physical examinations and discussions about how you're feeling. For some patients, especially those who had a bone marrow transplant or whose doctors need more information about their disease, blood samples and possibly bone marrow samples might be taken as part of your routine care.
The study will monitor things like whether your leukaemia has returned or progressed. For younger patients, your growth and development will also be assessed. You won't be receiving new treatment as part of this follow-up study, but rather your health will be observed over a long period. The total duration of your participation will depend on how long the researchers need to follow your health and the course of your disease, potentially for several years.
Potential risks and benefits
Locations (1)
- —UnverifiedFrance
Common questions
What is UCART19?
UCART19 is a special cell therapy that was used to treat certain types of blood cancer like advanced lymphoid leukaemia. This study is checking on people who have already had this treatment.
Why is this study important?
It's important because it helps doctors learn about the long-term safety and how well UCART19 works over many years. This helps them improve future treatments for others.
Will I get new treatment in this study?
No, this is a follow-up study. You won't receive new UCART19 treatment. It's about monitoring your health after you've already had the treatment.
What will I have to do if I join?
You'll have regular check-ups with your medical team. This might include talking about your health, physical checks, and sometimes blood tests, all as part of your ongoing care.
Can I stop participating?
Yes, you can choose to leave the study at any time, for any reason. It won't affect your medical care.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.